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Objective(s): Experimental allergic encephalomyelitis (EAE) is an autoimmune disease validated as 
animal model of multiple sclerosis (MS). Administration of genistein, a phytoestrogenic 
component of soy, to mice at the onset of EAE is known to attenuate the clinical signs of the 
disease. The potential effects of genistein on established EAE is less studied. In the current study, 
we aimed to compare the effects of genistein administration on EAE severity in early and late 
phases of the disease. 
Materials and Methods: The C57BL/6 mice were induced with EAE, using MOG 35-55 and gavaged 
with genistein (300 mg/kg) either after the appearance of the first clinical sign or 30 days post 
disease induction for ten days. 24 hr after the last gavage, mice were sacrificed. Brains and spleens 
were removed for assessing lymphocyte proliferation, cell cytotoxicity, and cytokine profile. Spinal 
cords were dissected to assess the amount of demyelination using Luxol fast blue/cresyl violet 
staining. 
Results: Administering mice with genistein, after the establishment of EAE, did not reverse the 
clinical signs of disease. However, treating with genistein at the onset of disease alleviated the 
clinical signs by reducing neuronal demyelination. Genistein suppressed the production of IFN-γ 
and enhanced IL-10 secretion in splenocyte and brain.  Genistein also reduced IL-12 and TNF-α 
secretion in splenocytes, suppressed the proliferation of T-cells, and reduced the cell cytotoxicity. 
Conclusion: Genistein oral therapy might only reduce EAE severity if started in early phases of the 
disease. 
 
Article history: 
Received: Aug 6, 2013 
Accepted: Dec 16, 2013 
 
 
 
Keywords:  
Experimental allergic 
encephalomyelitis (EAE) 
Genistein 
Immunomodulation 
Interferon-gamma 
Multiple sclerosis  
 
 
 
 
 
 
►Please cite this paper as: 
Razeghi Jahromi S, Arrefhosseini SR, Ghaemi A, Alizadeh A, Sabetghadam F, Togha M. Effect of oral genistein administration in early and late 
phases of allergic encephalomyelitis. Iran J Basic Med Sci 2014; 17:509-515.  
 
 
 
 
Introduction 
Multiple Sclerosis (MS) is a complex autoimmune 
disease identified as the most common debilitating 
neurological disease in young adults (1). Both 
genetic and environmental factors contribute to MS 
pathology, including inflammation, demyelination, 
and/or axonal transaction. Experimental allergic 
encephalomyelitis (EAE) is an inducible T-cell 
mediated autoimmune disease, validated as a 
relevant model of MS (2, 3). CD4+ T-cells are 
considered essential in the initial stages of CNS 
inflammation; however, both CD8+ T-cells and 
microglia also play curtailing roles. During the 
inflammation process, cytokines such as IFN-γ, TNF- 
α, IL-12, and IL-17 are involved in many of the key 
pathological features of MS and EAE.  
A distinct female predominance exists for                        
a variety of human autoimmune disorders including 
MS (4). However, estrogens have also shown to be 
suppressive in autoimmune diseases mediated by             
T cells. The Estrogen treatment of MS patients seems 
to be feasible; however, it might have serious                 
side effects. Phytoestrogens are plant derived 
compounds that have a stradiol-like structure 
exerting estrogenic and anti-estrogenic effects (5). 
The most widely distributed phytoestrogens are 
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isoflavones. Genistein is the major bioactive 
isoflavone found in soy bean. Previous studies have 
demonstrated the anti-inflammatory and anti-
oxidative effects of genistein (6, 7). A few recent 
studies were designed to investigate the effect of 
genistein on EAE course. The injection of genistein to 
ovariectomized mice was reported to decrease EAE 
severity (8). Also, 7-O-tetradecanoyl-genistein oral 
therapy was reported to ameliorate EAE signs (9). 
However, little has been elucidated regarding the 
effects of genistein on the severity of EAE after the 
establishment of disease. We designed this study to 
evaluate the potential therapeutic effect of genistein 
on established EAE. 
 
Materials and Methods 
Animals 
In this study, EAE was induced in 8–12 week 
female C57Bl/6 mice (22.4±0.37 g; Pasteur Institute 
of Iran). Each group contained 6 animals. The 
animals were housed in Shefa Neuroscience 
Research Center and kept at approximately 21°C, on 
12 hr light-dark cycle, with access to food and water 
ad libitum. All the protocols were approved by 
Neurological Research Center Committee, Tehran 
University of Medical Sciences. 
 
Induction of EAE 
The mice were immunized with a 1:1 ratio of 
MOG 35-55 (Alexis, Switzerland) dissolved in 
Complete Freund’s Adjuvant (CFA) containing 0.4 mg 
of mycobactererium tuberculosis (Sigma-Aldrich, 
USA). For this purpose, 300 μg of MOG was dissolved 
in 100 μl Phosphate buffer saline (PBS) 10%          
(Sigma-Aldrich, USA) and mixed with equal volume 
of CFA. On day 0, the MOG-CFA emulsion was 
subcutaneously injected into four sites of the upper 
flanks (200 μl / mouse). The additional immune 
adjuvant, pertussis toxin (PTX), (Sigma-Aldrich, USA) 
was injected intraperitoneally (400 ng/ mouse) on 
day 0 and again 48 hr later.   
 
Genistein administration 
Genistein was dissolved in dimethyl sulfoxide 
(DMSO) 11% (Sigma Aldrich, USA). Genistein                 
(300 mg/kg) or DMSO, as vehicle, was administered 
daily by oral gavage (n=6 mice/group). In the first set of 
the experiments, the mice received genistein or DMSO 
after the appearance of the first clinical sign for 10 days. 
The treatment did not begin until each individual 
mouse began to develop signs of EAE, and thus 
initiation of compound administration occurred over a 
period of days. In the second set of experiments, the 
mice were gavaged with genistein (300 mg/kg) or 
DMSO, from day 30 post induction (p.i.) for 10 days. 
The day after the last treatment, the mice in all groups 
were sacrificed for further evaluation. 
Clinical evaluation of EAE 
The clinical score of each mouse was assessed 
daily for 10 days. The following grading scheme was 
used to clinically score the animals: 0, no clinical 
signs; 0.5, hook tail; 1, flaccid/floppy tail; 2, walking 
deficits; 2.5, unilateral hind limb paralysis 3, bilateral 
hind limb paralysis; 3.5, paraplegia with forelimb 
weakness; 4, quadriplegia and 5, moribund. In the 
first set of experiments, the assessing of daily clinical 
score of each mouse began on day 0 and continued 
for 10 days after the appearance of the first clinical 
sign (score 1). In the second set of experiments, daily 
clinical score of each mouse was recorded from day 0 
to 40. Three clinical parameters were used to 
compare the course of disease. Mean daily clinical 
score: average of the sum of the daily clinical scores 
of the mice in each group. Disease onset: average of 
the first day of the appearance of clinical signs  
(score 0.5) of the mice in each group. Maximum 
disease score: average of the highest scores of the 
mice in each group (10).  
 
Histological evaluation 
 To assess the percent of demyelination, the mice 
were sacrificed with deep anesthesia one day after 
the last administration of drugs. The spinal cords of 
the animals were removed. Prior to sectioning, the 
spinal cords were put in paraformaldehyde 4% for 
overnight. Fixed spinal cords were processed in 
tissue processor (Payroll Process) for dehydration 
and cleaned with xylol prior to embedding in 
paraffin. Embedded spinal cords were serially 
sectioned. Axial spinal cord sections (8 microns) 
were cut on the rotary cryostat. Dorsal of lumbar 
sections were assessed for the presence of 
demyelination. A series of 4–5 cuts were pasted on 
one slide using albumin glue. 
The samples were stained with Luxol fast blue-
LFB (Merck, Germany)/ Cresyl violet (BDH, 
England). Briefly, spinal cord sections were 
deparaffinized and transformed through a graded 
serial of ethanol to 1% solution of LFB in 0.05% 
acetic acid and 96% ethanol. Sections were left in 
LFB solution in 56°C overnight, then rinsed in 95% 
ethyl alcohol and distilled water prior to 
differentiating in 70% ethyl alcohol. After 
differentiation in the lithium carbonate solution, 
sections were placed in distilled water again and 
counterstained with cresyl violet. Myelin stained 
blue and neurons appeared in pink and violet. The 
amount of demyelination was determined by 
assessing at least 5 sections for each mouse using 
infinity software (version 4.6). 
 
Brain cytokine assay 
 One day after the last treatment, the mice were 
sacrificed and their brains were removed. For 
assessing the concentration of cytokines in CNS, 100 
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mg of frontal and temporal lobes of each mouse was 
homogenized in 10 ml of an extracting solution 
containing 50 μM tris (Sigma-Aldrich, USA), 2 mM 
EDTA (Merck, Germany), 0.1 M NaCl (Sigma-Aldrich, 
USA), 1 mM dithiotheritol (Merck, Germany), 200 μM 
phenylmethylsulfonyl fluoride (Merck, Germany), 1 
μg/ml chymostatin (Sigma-Aldrich, USA), and 1 
μg/ml trypsin inhibitor (Sigma-Aldrich, USA). 
Afterwards, the homogenate was sonicated for 60 
sec at 40000 hz on ice. Brain homogenate was 
centrifuged (10000*10 min at 4oC). The supernatant 
was analyzed for IFN-γ, TNF-α, IL-12 (as the 
proinflammatory cytokines), and IL-10 (as an anti-
inflammatory cytokine) concentrations using 
sandwich-based enzyme-linked immunosorbent 
assay (ELISA) kits (eBioscience, USA) by following 
the manufacturer’s instruction. All tests were 
performed in triplicate for each mouse. 
 
Spleen cytokine assay   
The mice were sacrificed 24 hr after the last 
gavage and their splenocytes were isolated. 
Mononuclear cells from spleens of immunized mice 
(3 mice/ group) were prepared and incubated with 
1.5 ml of RPMI-1640 at a concentration of 2×105 
cells/well in 24-well plate (Nunc, Denmark) for two 
days. The RPMI was supplemented with 10% FCS, 
1% L-glutamine, 1% HEPES, 0.1% 2ME, and 0.1% 
penicillin/streptomycin and pulsed with 10 µg/ml 
genistein. The cell supernatants were collected. The 
amount of cytokines in cell supernatants was 
assessed using sandwich-based ELISA kits 
(eBioscience, USA) performed according to the 
manufacturer’s protocol. All tests were performed in 
triplicate for each mouse (11).  
 
Lymphocyte proliferation assay (LPA) 
 24 hr after the last oral administration, single cell 
suspension of mononuclear cells was obtained from 
immunized mice and used for lymphocyte 
proliferation assay. Briefly, the suspension of 
isolated spleen cells was treated with lyses buffer 
0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA, (pH 
7.2) in order to clear red blood cells. 2x105 
cells/well were cultured in 96-well flat-bottom 
culture plates (Nunc, Denmark). The preparations 
were cultured with RPMI-1640 supplemented with 
10% fetal calf serum, 1% L-glutamine, 1% HEPES, 
0.1% 2ME, and 0.1% penicillin/streptomycin                
and were incubated in the presence of 10 µg/ml 
genistein. T cell mitogen phytohemagglutinin- PHA 
(Sigma chemicals, Australia) was used as positive 
control at the concentration of 5 µg/ml. After                   
3 days, MTT (3-(4, 5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) (Sigma chemicals, 
Australia) in concentration of 5 µg/ml was added per 
well and incubated for 5 hr at 37°C in 5% CO2. DMSO 
(dimethyl sulfoxide) (100 µl) was added to dissolve 
the produced formazan crystals. 
The plates were read at 540 nm, and the results 
were expressed as stimulation index (SI). The SI was 
determined as follows: OD values of stimulated cells 
(Cs) minus relative cell numbers of unstimulated 
cells (Cu) divided by relative OD values of 
unstimulated cells. 
 
SI = (Cs - Cu)/Cu 
 
All tests were performed in triplicate for each mouse. 
 
Cell cytotoxicity assay 
 In order to assess cell cytotoxicity, lactate 
dehydrogenase (LDH) level was determined in 
splenocytes. 24 hr after the final administration, the 
mice were sacrificed and their splenocytes were 
isolated. For each sample obtained from an 
individual mouse, the single cell suspension of 
mononuclear cells (used as the effecter cells) was co-
cultured in RPMI 1640 medium with washed target 
cells EL4 at various effector-to-target cells for 4 hr in 
phenol red-free RPMI 1640 containing FCS 3%. For 
preparation of the target cells, EL-4 cells were 
stimulated with genistein antigen.  
After centrifugation, the supernatants                       
(50 µl/well) were transferred to the 96-well flat-
bottom plates, and lysis of target cells was determined 
by measuring LDH release using Cytotoxicity Detection 
Kit (LDH) according to the procedures stated by the 
manufacturer (Takara Company, Japan). Several 
controls were used for the cytotoxicity assay. 
“High control” was the total LDH released from 
target cells, and all EL4 cells were lysed by a medium 
containing 1% Triton X-100. “Low control” was the 
natural release of LDH from target cells, which was 
obtained by adding EL4 cells only to the assay 
medium. “T-cell control” was used to measure the 
natural release of LDH from T cells obtained by 
adding different ratios of T cells only in the assay 
medium. The assay for all samples, including the 
controls, was performed in triplicates (11). 
The LDH-mediated conversion of the tetrazolium 
salt into red formazan product was measured at 490 
nm after incubation at room temperature for 30 min. 
The percentage of specific cytolysis was determined 
by the following formula: 
 
 
 
 
Statistical analysis  
The results represented at least two independent 
variables and were presented as mean± SEM. For 
analyzing the effect of treatment on clinical score, 
cytokine profile, lymphocyte proliferation, and cell 
cytotoxicity one-way analysis of variance was used. All 
analysis was followed by the Scheff’s intra group 
comparison. The differences were considered 
significant at P< 0.05. Data were analyzed with SPSS 17. 
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Figure 1. Effect of oral administration of 300 mg/kg genistein or DMSO on clinical course of experimental autoimmune encephalomyelitis . 
(A-1)  Genistein-treated animals (in early phase of disease) manifested lower clinical scores between days 20 and 24. A-2. In mice receiving 
treatment after the establishment of disease, clinical scores were not significantly different in comparison with DMSO 
 
Results 
Clinical signs of EAE 
In the first set of the experiments, female c57BL/6 
mice were gavaged with genistein or DMSO after the 
appearance of the flaccid tail (score 1) for 10 days. 12 to 
16 days following immunization, the mice developed 
the clinical signs of EAE. No significant differences in 
the mean onset time were observed between studied 
groups. The mean daily clinical score of genistein 
treated animals were almost always lower than 
controls. The difference became significant between 
days 20 and 24 (Figure 1). As presented in Table 1, 
genistein also significantly reduced the maximum 
clinical score (P<0.05). 
In the second set of the experiments, genistein or 
DMSO was administered to the mice from Day +30 to 
Day +40 post induction. Genistein administration at the 
late phase of disease did not have a significant effect on 
the mean daily and the mean maximum clinical scores. 
 
Demyelination of the spinal cord 
 To compare the rate of demyelination among the 
studied groups, the spinal cords were removed one 
day after the last gavage. Luxol Fast blue/Cresyl 
violet staining was used to determine the amount of 
demyelination in the dorsal of lumbar sections.  As 
apparent in Figure 2 (A-1 and A-2), in the first set of 
experiments, demyelination was obvious in the 
spinal cord of the DMSO-treated group, while it was 
notably reduced in genistein-treated mice. Unlike the 
first experiments, gavaging with genistein at the late 
phase of disease did not notably affect the extent of 
demyelination (Figure 2, B-1 and B-2).  
 
Cytokine patterns 
 A day after the last gavage, the animals were 
sacrificed. Spleen cell supernatants were examined 
for the amount of IFN-γ, TNF-α, IL-10, and IL-12. 
 In the first set of experiments, as presented in 
Figure 3-A, genistein reduced the splenic production 
of IL-12, TNF-α and IFN-γ. It further increased IL-10 
level. In the second set of experiments, treating with 
genistein did not significantly affect cytokine levels 
in spleen (Figure 3-A).  
We further assessed the pattern of cytokine secretion in 
brains of the treated animals. Compared to DMSO 
(Figure 3-B), gavaging with genistein at the onset  
of clinical signs of the disease reduced the production of 
IFN-γ and raised the secretion of IL-10 significantly. 
 
Proliferative response of T cells 
 We evaluated LPA using MTT methods. For this 
purpose, twenty-four hr after the last gavage, the 
animals (3 mice/ group) were sacrificed and the 
spleen cells were harvested. The lymphocytes were 
stimulated in vitro by 10 µg/ml genistein. As 
presented in Figure 4-A, in mice gavaged with 
genistein after the onset of clinical signs, the 
proliferative response of T cells was suppressed, 
compared to vehicle control (P≤0.05).   
Lymphocyte proliferative responses were not 
significantly different in mice receiving genistein 
from 30 days p.i. compared to the control group 
(Figure 4-A).  
 
 
 
 Table 1. Effect of oral administration of 300 mg/kg genistein or DMSO on clinical signs of experimental autoimmune encephalomyelitis 
 
Gavaging with genistein (300 mg/kg) at the onset of clinical signs significantly reduced maximum disease score. † Ratio, ‡ mean± SEM, * 
P<0.05, ** P<0.005 compared to DMSO-gavaged group post induction 
  Incidence† Onset (day)‡ Maximum clinical score‡ 
Treatment began at the onset 
of disease 
DMSO 6/6 14.5±0.56 2.8±0.21 
Genistein 5/6 14.8±0.37 1.6±0.25 ** 
    Treatment began after 30 
days  p.i.  
DMSO 6/6 14.7±0.52 2.7±0.17 
Genistein 6/6 12.8±0.57 2.8±0.26 
A-1 
A-2 
Razeghi Jahromi et al          Effect of oral genistein on allergic encephalomyelitis 
                  
 Iran J Basic Med Sci, Vol. 17, No. 6, Jun 2014   
 
513 
A-1 A-2 A-3 A-4 
A
  
A
  
B
  
B
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Demyelination of the lumbar spinal cords in mice induced with experimental autoimmune encephalomyelitis and treated with 
genistein (300 mg/kg) or DMSO. LFB/Cresyl violet staining was applied to assess spinal cord demyelination. A-1 and A-2 demonstrate 
demyelination in the mice receiving DMSO (A-1) or genistein (A-2) from the onset of disease for 10 days. A-3 and A-4 are the spinal cord 
sections of the mice that received DMSO (A-3) or genistein (A-4) from day 30 post induction for 10 days. Blue areas represent myelin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cytokine levels of brain and splenocytes in the mice induced 
with experimental autoimmune encephalomyelitis and receiving 
genistein (300 mg/kg) and DMSO either after the appearance of the 
first clinical sign or in late phase of disease. The TNF-α, IFN-γ, IL-12, 
and IL-10 levels were assessed in splenocytes (A) and the brain (B). All 
data expressed as the mean± SEM. ** P<0.005 and * P<0.05 compared 
to DMSO administration at the onset of disease, †P<0.05and 
††P<0.005 compared to DMSO at late phase, § P<0.05 and §§ P<0.005 
compared to genistein at late phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Lymphocyte proliferation and cell cytotoxicity assay in 
mice induced with experimental autoimmune encephalomyelitis 
and receiving genistein (300 mg/kg) and DMSO either after the 
appearance of first clinical sign or 30 days post induction, A) 
Lymphocyte proliferation evaluation using MTT assay. B) Cell 
cytotoxicity assays using quantitative measurement of LDH 
release. Data were collected from LDH results at various E/T 
ratios (E/T=25:1, 50:1, 100:1). The most significant differences 
between all these groups were at 50:1 E/T ratios. All data 
expressed as the mean± SEM, * P<0.05 compared to DMSO 
administration at the onset of disease, ††P<0.005 compared to 
DMSO at late phase, § P<0.05 compared to genistein at late phase 
33μm 
79μm 30.02 μm 
55.01 
* ††§
  
* 
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Cell cytotoxicity  
 In order to assess the effect of genistein on the 
lactate dehydrogenase release, three mice were used 
from each group. 24 hr after the final treatment, single 
cell suspensions of mononuclear cells (effecter cells) 
were co-cultured with pulsed EL-4 cells (target cell). 
 In the first experiment, as shown in Figure 4, 
lymphocytes of immunized mice with genistein 
(25±2.4%) suppressed a specific cytolytic activity at 
an E/T ratio of 50:1 significantly, compared to DMSO 
group (33.01±1.03%). However, lymphocytes from 
mice gavaged with genistein after the establishment 
of the disease did not show any significant difference 
compared to the DMSO group (Figure 4-B). 
 
Discussion 
Flavonoids including genistein were reported to 
have beneficial effects in EAE. Evidences 
demonstrated that genistein has a variety of 
molecular targets, including enzymes, cytokines, cell 
proliferation, gens regulating, transcription factors, 
and apoptosis. Each of which can potentiate 
genistein to protect against and improve signs of EAE 
(12). In previous studies mice were administered 
with genistein at the onset of disease (8–9). Whether 
genistein can modify EAE feature in progressed EAE 
is still unknown.   
Our results indicate that unlike in early phase, the 
administration of genistein in the late phase of EAE is 
not effective in controlling clinical signs. The 
observed difference may be due to the fact that in the 
progressive phase of EAE, inflammation and 
demyelination continue to worsen (13). In 
progressed disease, genistein was unable to modify 
cytokine pattern, lymphocyte proliferation, and the 
percent of cytotoxicity. Each of which might make 
genistein effective in ameliorating EAE severity at 
the early phase of disease.  
Gavaging with genistein in the early phase of EAE 
reduced the stimulation index of lymphocytes which 
mainly represents memory CD4+ T-cell proliferation. 
Oral genistein in early phase also decreased IFN-γ 
secretion and the percent of cytotoxicity which 
mostly manifests the CD8+ activity. EAE is mainly 
characterized by infiltration of myelin-auto reactive 
CD4+ and CD8+ T-cells into the central nervous 
system (14). CD8+ T-cells were detectable in MS 
plaques and reported to mediate inflammation in 
EAE and MS. They activated to express IFN-γ (15). 
Among the many cytokines implicated in the 
pathogenesis of MS and EAE, IFN-γ has the principal 
regulatory role, directing chemokine production, 
involvement in T cell proliferation and subsequently 
affecting the onset and progression of the disease 
(16). IFN-γ secreting auto reactive T-cells are 
elevated in blood and cerebrospinal fluid of MS 
patients, in comparison with controls (17). The 
administration of IFN-γ to MS patients leads to the 
exacerbation of the disease (18). In accordance with 
the results of the current study, the only two other 
studies on the effect of genistein administration to 
EAE-induced mice in early phase of disease, reported 
a deduction in brain (8, 9) and spleen (8) levels of 
IFN-γ.  
In the present study, gavaging with genistein at 
the onset but not in late phase of disease also 
enhanced the production of IL-10 in brain and 
splenocytes. IL-10 is a critical cytokine in down-
regulating Th1 responses in MS/EAE. Furthermore, 
in remission phase of EAE, the expression of IL-10 
mRNA rises in CNS and IL-10 deficit mice are not 
able to recover from the disease (19, 20). Studies of 
IL-10 in relapsing- remitting MS (RRMS) patients 
showed a reduction of this cytokine level before 
attacks (21). In addition, endogenous IL-10 
suppresses IFN-γ production in RRMS patients (22). 
De Paula et al (8) and Castro et al (9) reported a 
significant increase of IL-10 secretion in brain and 
splenocyte of genistein-injected mice, which is in 
agreement with our results. 
Moreover, our results clarified that treating mice 
with genistein immediately after the onset of clinical 
signs significantly inhibits IL-12 production in 
spleen. Comparable effect on IL-12 level was not 
observed when genistein was administered to mice 
with progressed EAE. One of the crucial pro-
inflammatory cytokines altered in EAE/MS is IL-12 , 
an increase in secretion of which results in 
augmentation of the demyelination. Moreover, 
inhibiting IL-12 secretion or signaling involves the 
prevention of pathological and clinical signs of EAE 
(23). The IL-12 level of peripheral blood 
mononuclear cells was elevated in RRMS and 
Secondary Progressive MS patients in comparison 
with controls. IL-12 p40 also showed a relationship 
with the development of active lesions in MRI (24). 
In current study, unlike De Paula et al results (8), 
genistein did not affect the brain IL-12 level 
significantly. The observed difference might be due 
to the difference in the length of the treatment 
between De Paula and our study. We gavaged mice 
for 10 days after the appearance of first clinical signs, 
but in De Paula et al study mice were injected with 
genistein from day +14 to day +21. The peak 
inflammatory response is usually reached by day 18–
20. Unlike current study, in mentioned previous 
study mice were sacrificed at the peak of clinical 
score. 
 
Conclusion 
The oral administration of genistein at the onset of 
clinical signs, but not in late phase of EAE, alleviates the 
severity of the disease by regulating cytokine 
production, lymphocyte proliferation, and CD8+ 
cytotoxicity. Human studies on the potential effect of 
oral genistein in early phase of MS are proposed. 
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